By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date– The post Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer appeared first on Geneos Therapeutics .